tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
PremiumCompany AnnouncementsReplimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer
7d ago
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
Premium
Company Announcements
Replimune’s Long-Term Safety Study: A Potential Game-Changer in Oncolytic Immunotherapy
7d ago
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
Premium
Company Announcements
Bristol-Myers Squibb and Replimune’s Promising Cancer Study: A Potential Game Changer
7d ago
Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
PremiumThe FlyPiper upgrades Replimune to Overweight on ‘very pleasant surprise’
14d ago
Replimune upgraded to Overweight from Neutral at Piper Sandler
Premium
The Fly
Replimune upgraded to Overweight from Neutral at Piper Sandler
14d ago
Replimune Group’s FDA Resubmission for RP1 Accepted
Premium
Company Announcements
Replimune Group’s FDA Resubmission for RP1 Accepted
14d ago
Leerink upgrades Replimune on renewed confidence in RP1
PremiumThe FlyLeerink upgrades Replimune on renewed confidence in RP1
14d ago
Replimune upgraded to Outperform from Market Perform at Leerink
Premium
The Fly
Replimune upgraded to Outperform from Market Perform at Leerink
14d ago
Unusually active option classes on open October 20th
Premium
The Fly
Unusually active option classes on open October 20th
14d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100